Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Inotek Pharmaceuticals Corp    ITEK

INOTEK PHARMACEUTICALS CORP (ITEK)
Mes dernières consult.
Most popular
  Report  
SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

(d) Exhibits

Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) Files An 8-K Entry into a Material Definitive Agreement

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/14/2017 | 09:26am CEST

Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) Files An 8-K Entry into a Material Definitive AgreementItem 1.01

Entry into a Material Definitive Agreement.

Exhibit No.

Description

2.1 Agreement and Plan of Merger and Reorganization, dated as of September12, 2017, by and among Inotek Pharmaceuticals Corporation, Rocket Pharmaceuticals, Ltd. and Rome Merger Sub (1)
10.1 Amendment to Offer Letter, effective as of September12, 2017, by and between Inotek and Rudolf A. Baumgartner, MD
99.1 Press release of Inotek Pharmaceuticals Corporation dated September12, 2017
(1) Schedules have been omitted from this filing to Item601(b)(2) of Regulation S-K. Inotek agrees to furnish supplementally a copy of any omitted schedule to the SEC upon its request; provided, however, that Inotek may request confidential treatment to Rule 24b-2 of the Exchange Act for any schedule so furnished.

* * *

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September13, 2017 INOTEK PHARMACEUTICALS CORPORATION
By:

/s/ Dale Ritter

Dale Ritter
Vice President – Finance

EXHIBIT INDEX

Exhibit No.

Description

2.1 Agreement and Plan of Merger and Reorganization, dated as of September12, 2017, by and among Inotek Pharmaceuticals Corporation, Rocket Pharmaceuticals, Ltd. and Rome Merger Sub (1)
10.1 Amendment to Offer Letter, effective as of September12, 2017, by and between Inotek and Rudolf A. Baumgartner, MD
99.1 Press release of Inotek Pharmaceuticals Corporation dated September12, 2017
(1) Schedules have been omitted from this filing to Item601(b)(2) of Regulation S-K. Inotek agrees to furnish supplementally a copy of any omitted schedule to the SEC upon its request; provided, however, that Inotek may request confidential treatment INOTEK PHARMACEUTICALS CORP ExhibitEX-2.1 2 d421363dex21.htm EX-2.1 EX-2.1 Exhibit 2.1 CONFIDENTIAL EXECUTION VERSION       AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: INOTEK PHARMACEUTICALS CORPORATION,…To view the full exhibit click here
About Inotek Pharmaceuticals Corporation (NASDAQ:ITEK)
Inotek Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. Its lead product candidate, trabodenoson, is a selective adenosine mimetic that the Company has designed to lower intraocular pressure (IOP) by restoring the eye’s natural pressure control mechanism. The Company developed this molecule to selectively stimulate a particular adenosine subreceptor in the eye with the effect of augmenting the intrinsic function of the eye’s trabecular meshwork (TM). Its product pipeline includes trabodenoson monotherapy delivered in an eye drop formulation, as well as a fixed-dose combination (FDC), of trabodenoson with latanoprost given once-daily (QD). The Company is evaluating the potential of trabodenoson to slow the loss of vision associated with glaucoma and degenerative retinal diseases.

The post Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) Files An 8-K Entry into a Material Definitive Agreement appeared first on Market Exclusive.

© Market Exclusive 2017, source Market Exclusive

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on INOTEK PHARMACEUTICALS COR
07/05ROCKET PHARMACEUTICALS : to Join Russell 3000® and 2000® Indexes
AQ
06/28ROCKET PHARMACEUTICALS : to Join Russell 3000® and 2000® Indexes
AQ
06/27ROCKET PHARMACEUTICALS : to Join Russell 3000 and 2000 Indexes
AQ
06/25ROCKET PHARMACEUTICALS, INC. : Change in Directors or Principal Officers, Amendm..
AQ
06/14BIOXCEL THERAPEUTICS : Appoints Dr. Cedric Burg as Vice President and Head of Gl..
AQ
06/04ROCKET PHARMACEUTICALS : to Present at the Jefferies 2018 Healthcare Conference
AQ
05/25ROCKET PHARMACEUTICALS : Announces Strategic Research Collaboration
AQ
05/18ROCKET PHARMACEUTICALS, INC. : Regulation FD Disclosure, Financial Statements an..
AQ
05/18ROCKET PHARMACEUTICALS : Announces Strategic Research Collaboration
AQ
05/17ROCKET PHARMACEUTICALS : Reports First Quarter 2018 Financial Results and Operat..
AQ
More news
News from SeekingAlpha
01/30Solid Biosciences slips on potential AAV toxicity 
01/30Premarket analyst action - healthcare 
01/25YOUR DAILY PHARMA SCOOP : Portola Still Attractive, Johnson & Johnson Reports Q4.. 
01/24After Hours Gainers / Losers (1/24/2018) 
01/24Biotech Forum Daily Digest For January 24th 
Financials ($)
Sales 2018 -
EBIT 2018 -58,9 M
Net income 2018 -52,2 M
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 0
Capi. / Sales 2019 0
Capitalization 774 M
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 27,0 $
Spread / Average Target 39%
EPS Revisions
Managers
NameTitle
Gaurav Shah President, Chief Executive Officer & Director
Roderick T. Wong Chairman
Kinnari Patel Chief Operating Officer & Head-Development
John Militello Controller, Chief Financial & Accounting Officer
Jonathan David Schwartz Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
INOTEK PHARMACEUTICALS CORP774
GILEAD SCIENCES7.84%100 614
VERTEX PHARMACEUTICALS20.45%45 997
REGENERON PHARMACEUTICALS-2.21%38 951
GENMAB5.93%10 467
NEUROCRINE BIOSCIENCES, INC.32.61%9 250